Evercore ISI Group Maintains Outperform on Longboard Pharmaceuticals, Raises Price Target to $80
Evercore ISI Group Maintains Outperform on Longboard Pharmaceuticals, Raises Price Target to $80
Evercore ISI集團維持對Longboard藥品的優異評級，將價格目標上調至80美元。
Evercore ISI Group analyst Josh Schimmer maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Outperform and raises the price target from $57 to $80.
Evercore ISI Group分析師Josh Schimmer維持對長板藥品（NASDAQ:LBPH）的表現，並將目標價從57美元上調至80美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。